spacer
home > pmps > autumn 2003 > the impact of the eu clinical trials directive on the supply chain
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Impact of the EU Clinical Trials Directive on the Supply Chain

The European Union is about to enter a new era in the conduct of clinical trials within its jurisdiction. The vastly different range of current approaches from member states to trials are going to converge on 1st May 2004. At least that is the intention. Will we make it on time or will national differences on interpretation make it impossible? Not only that, but how will the new accession countries intending to join the EU in May 2004 fare? In both cases, only time will tell.

This article broadly highlights certain aspects of the changes to clinical supplies as demanded by the Directive (1) and encouraged by the accompanying publication of guidance in the revised Annex 13 (2) to European Good Manufacturing Practice (GMP). Readers may find that these changes already exist in many Member States' legislation, but in most countries the requirements are new.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Paul O'Connor, Head of Quality at Clinical Trial Services

Paul O'Connor graduated from the University of Ulster in 1994 with a BSc in Applied Biochemical Sciences. He has spent nine years in various pharmaceutical quality roles, first with Galen Ltd and subsequently with Clinical Trials Services. He is the Head of Quality for the organisation which is based in the UK, Pennsylvania and North Carolina. The company regularly provides clinical trial packaging, analytical and distribution services for 18 of the top 20 pharmaceutical companies. He is also one of the company's Qualified Persons and advises many overseas pharmaceutical companies, particularly those from the US and Japan, on release of their supplies into European Union countries.

spacer
Paul O'Connor
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stability Testing and Forced Degradation Stress Tests - Proactive Risk Management

Whereas the durability of many consumables, have a strong tendency to decrease, stability is and remains a crucial factor for pharmaceuticals. That is why the identification and elimination of factors, which put long-term stability at risk, is central during development – and an important requirement concerning the product’s quality.
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)


More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement